To present an uncommon but serious, recently identified complication of checkpoint inhibitor therapy in a patient treated with pembrolizumab infusion for disseminated recurrent respiratory papillomatosis (RRP).
Methods:
Case report.
Results:
A 43-year-old woman with underlying asthma developed acute hypoxic respiratory failure within 24 hours of her third infusion of pembrolizumab for treatment of intractable, disseminated recurrent respiratory papillomatosis. Pulmonary function testing revealed a severe intra-thoracic obstructive ventilatory defect. Discontinuation of pembrolizumab, ventilatory support, and treatment with systemic and inhaled corticosteroids resulted in resolution of respiratory failure; however, her underlying asthma remains poorly controlled.
Conclusion:
To our knowledge, this case is the first report of pembrolizumab-induced obstructive respiratory failure in a patient being treated for RRP.
NovakovicDChengATLZurynskiY, et al. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis. 2018;217:208-212.
3.
MarkowitzLEGeeJChessonHStokleyS.Ten years of human papillomavirus vaccination in the United States. Acad Pediatr. 2018;18:S3-S10.
4.
SchraffSDerkayCSBurkeBLawsonL.American Society of Pediatric Otolaryngology members’ experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg. 2004;130:1039-1042.
5.
IvancicRIqbalHdeSilvaBPanQMatrkaL.Current and future management of recurrent respiratory papillomatosis. Laryngoscope Investig Otolaryngol. 2018;3:22-34.
6.
NebesioCLMirowskiGWChuangTY.Human papillomavirus: clinical significance and malignant potential. Int J Dermatol. 2001;40:373-379.
7.
VenkatesanNNPineHSUnderbrinkMP.Recurrent respiratory papillomatosis. Otolaryngol Clin North Am. 2012;45:671-694, viii-ix.
8.
ArmstrongLRDerkayCSReevesWC.Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg. 1999;125:743-748.
9.
LarsonDADerkayCS.Epidemiology of recurrent respiratory papillomatosis. APMIS. 2010;118:450-454.
10.
San GiorgiMRMAaltonenLMRihkanenH, et al. Quality of life of patients with recurrent respiratory papillomatosis. Laryngoscope. 2017;127:1826-1831.
11.
BishaiDKashimaHShahK.The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 2000;126:935-939.
12.
ChessonHWForhanSEGottliebSLMarkowitzLE.The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine. 2008;26:4513-4518.
13.
LawlorCBalakrishnanKBotteroS, et al. International Pediatric Otolaryngology Group (IPOG): juvenile-onset recurrent respiratory papillomatosis consensus recommendations. Int J Pediatr Otorhinolaryngol. 2020;128:109697.
14.
HealyGBGelberRDTrowbridgeALGrundfastKMRubenRJPriceKN.Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med. 1988;319:401-407.
15.
DionGRTengSBoydLR, et al. Adjuvant human papillomavirus vaccination for secondary prevention: a systematic review. JAMA Otolaryngol Head Neck Surg. 2017;143:614-622.
16.
AhnJPengSHungCFRodenRBSWuTCBestSR.Immunologic responses to a novel DNA vaccine targeting human papillomavirus-11 E6E7. Laryngoscope. 2017;127:2713-2720.
17.
MaunsellRBellomo-BrandaoMA.Pegylated interferon for treating severe recurrent respiratory papillomatosis in a child: case report. Sao Paulo Med J. 2018;136:376-381.
18.
AhmedMMConnorMPPalazzoloM, et al. Effect of high-dose vocal fold injection of cidofovir and bevacizumab in a porcine model. Laryngoscope. 2017;127:671-675.
19.
ZurKBFoxE.Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child. Laryngoscope. 2017;127:1538-1542.
20.
BestSRMohrMZurKB.Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey. Laryngoscope. 2017;127:2225-2229.
21.
AhnJBishopJARodenRBSAllenCTBestSRA. The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis. Laryngoscope. 2018;128:E27-E32.
22.
La-BeckNMJeanGWHuynhCAlzghariSKLoweDB.Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy. 2015;35:963-976.
23.
MitropoulouGDaccordCSautyA, et al. Immunotherapy-induced airway disease: a new pattern of lung toxicity of immune checkpoint inhibitors. Respiration. 2020;99:181-186.
24.
MaenoKFukudaSOguriTNiimiA.Nivolumab-induced asthma in a patient with non-small-cell lung cancer. Ann Oncol. 2017;28:2891.
25.
YamayaTHeeHMAoyagiT, et al. Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators. Respir Med Case Rep. 2019;28:100866.
26.
BlanchardABouchardN.Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer. Curr Oncol. 2019;26:e571-e573.
27.
DerkayCSMalisDJZalzalGWiatrakBJKashimaHKColtreraMD.A staging system for assessing severity of disease and response to therapy in recurrent respiratory papillomatosis. Laryngoscope. 1998;108:935-937.
28.
AllenCTLeeSNorbergSM, et al. Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. J Immunother Cancer. 2019;7:119.
29.
Pembrolizumab for HPV-associated recurrent respiratory papilloma patients with laryngeal, tracheal and/or pulmonary involvement. ClinicalTrials.gov identifier: NCT02632344. Updated August 18, 2020. Accessed May 21, 2021. https://ClinicalTrials.gov/show/NCT02632344
30.
Avelumab for people with recurrent respiratory papillomatosis. ClinicalTrials.gov identifier: NCT02859454. Updated February 26, 2020. Accessed May 21, 2021. https://ClinicalTrials.gov/show/NCT02859454
31.
MorrisVKSalemMENimeiriH, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:446-453.
32.
ChowLQMHaddadRGuptaS, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016;34:3838-3845.
33.
NaidooJWangXWooKM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35:709-717.
34.
NishinoMGiobbie-HurderAHatabuHRamaiyaNHHodiFS.Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1607-1616.
35.
SureshKVoongKRShankarB, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol. 2018;13:1930-1939.
36.
De VelascoGJeYBosseD, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5:312-318.
37.
KhungerMRakshitSPasupuletiV, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152:271-281.
38.
DelaunayMCadranelJLusqueA, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50:1700050.
39.
ReussJSureshKPsoterKFordePNaidooJ.Early changes in pulmonary function are associated with development of pneumonitis in NSCLC patients receiving immune checkpoint blockade. J Thorac Oncol. 2019;14:S587-S588.
40.
StollPUlrichMBratkeKGarbeKVirchowJCLommatzschM.Imbalance of dendritic cell co-stimulation in COPD. Respir Res. 2015;16:19.
41.
McKendryRTSpallutoCMBurkeH, et al. Dysregulation of antiviral function of CD8(+) T cells in the chronic obstructive pulmonary disease lung. Role of the PD-1-PD-L1 axis. Am J Respir Crit Care Med. 2016;193:642-651.
42.
RosskopfSJahn-SchmidBSchmettererKGZlabingerGJSteinbergerP.PD-1 has a unique capacity to inhibit allergen-specific human CD4(+) T cell responses. Sci Rep. 2018;8:13543.
43.
KanaiOKimYHDemuraY, et al. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer. 2018;9:847-855.
44.
HaanenJCarbonnelFRobertC, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-iv42.
45.
NishinoMChambersESChongCR, et al. Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol Res. 2016;4:289-293.
46.
AsherNMaromEMBen-BetzalelG, et al. Recurrent pneumonitis in patients with melanoma treated with immune checkpoint inhibitors. Oncologist. 2019;24:640-647.
